Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline Continue Reading
UC Irvine-led study of more than 220,000 U.S. adults links higher B vitamin levels with lower stroke risk Continue Reading
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research Continue Reading
American Society for Preventive Cardiology Announces 2026 Virtual Imaging Symposium Focused on Multimodality Cardiovascular Imaging for Prevention Continue Reading
New AJPC Study Examines How PREVENT Equations Translate Cardiovascular Risk Factors into Predicted CVD Risk Continue Reading
AJPC Publishes POLY-ACS Trial Demonstrating Feasibility of Polypill Strategy After Acute Coronary Syndrome Continue Reading
Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH) Continue Reading
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Continue Reading
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) Continue Reading
On February 12, 2026, the FDA approved a new indication for pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH), and a new indication for pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Continue Reading
American Journal of Preventive Cardiology Publishes Landmark Study on Sex Differences in Homozygous Familial Hypercholesterolemia in First Issue Under New Editor-in-Chief Continue Reading
The ASPC 2026 Congress on CVD Prevention will be held in-person at The Phoenician in Scottsdale, AZ from July 31 - August 2, 2026! Continue Reading
